OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) Director James Paul Lang bought 321,408 shares of the company's stock in a transaction dated Friday, March 14th. The stock was purchased at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares of the company's stock, valued at $2,959,835.20. This represents a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
OptimizeRx Price Performance
OPRX opened at $8.61 on Thursday. The stock has a market cap of $158.60 million, a price-to-earnings ratio of -6.47 and a beta of 1.31. OptimizeRx Co. has a 1 year low of $3.78 and a 1 year high of $14.13. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock has a fifty day moving average price of $5.71 and a 200 day moving average price of $5.92.
Institutional Trading of OptimizeRx
A number of institutional investors have recently bought and sold shares of OPRX. Whetstone Capital Advisors LLC acquired a new stake in OptimizeRx during the fourth quarter valued at $6,563,000. Royce & Associates LP acquired a new stake in shares of OptimizeRx in the fourth quarter worth about $5,198,000. Tang Capital Management LLC acquired a new stake in shares of OptimizeRx in the fourth quarter worth about $1,075,000. Kennedy Capital Management LLC lifted its position in shares of OptimizeRx by 57.8% in the fourth quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock worth $2,887,000 after buying an additional 217,676 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of OptimizeRx in the fourth quarter worth about $673,000. Institutional investors and hedge funds own 76.47% of the company's stock.
Analyst Ratings Changes
Several research analysts have recently weighed in on the stock. B. Riley raised shares of OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Stephens assumed coverage on shares of OptimizeRx in a research report on Friday, December 20th. They issued an "equal weight" rating and a $5.50 target price on the stock. Lake Street Capital reissued a "buy" rating and issued a $11.00 target price on shares of OptimizeRx in a research report on Tuesday, December 24th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $8.00 price objective on shares of OptimizeRx in a research note on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, OptimizeRx currently has a consensus rating of "Moderate Buy" and an average target price of $9.06.
Read Our Latest Stock Report on OptimizeRx
About OptimizeRx
(
Get Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
